What Happened? Shares of healthcare tech company GoodRx (NASDAQ:GDRX) jumped 40.2% in the afternoon session after the company ...

Novo Nordisk shares plunged over 20% on Tuesday after the company named a new CEO and lowered its profit expectations, citing weaker sales of its popular weight-loss drug Wegovy due to competition ...

Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could ...

Investors wiped $70 billion off Novo Nordisk's market value on Tuesday after the maker of weight-loss drug Wegovy issued a profit warning and named a new CEO, as it battles rising competition in ...

Viatris’ generic to Wegovy has yet to secure FDA approval. Branded Wegovy, for its part, could lose U.S. patent protection in 2032, according to Novo’s 2024 annual report (PDF).

Novo Nordisk lowers 2025 guidance as Wegovy and Ozempic face slower U.S. uptake, competition, and continued compounded GLP-1 sales.

Patients taking the GLP-1 weight loss drug Zepbound face mandatory switch to Wegovy after CVS Caremark removed the Eli Lilly medication from its preferred coverage list, citing rising costs.

Investors wiped $70 billion off Novo Nordisk's market value on Tuesday after the maker of weight-loss drug Wegovy issued a profit warning and named a new CEO, as it battles rising competition in the ...

NYSE-listed shares of Danish drugmaker Novo Nordisk (NVO) fell about 3% on Tuesday morning after brokerage UBS downgraded the stock over an uncertain outlook for its blockbuster weight-loss drug ...

But each drug also has other uses. (See the “Uses of Zepbound vs. Wegovy” section for details.) Dosage: Both drugs are used once per week, but Zepbound and Wegovy have different strengths.

Wegovy (semaglutide) is a glucagon-like peptide-1 (GLP-1) agonist used for weight loss and weight management and to reduce the risk of major cardiovascular events. Stopping Wegovy, especially ...